Since its inception in 2008, HPV-IMPACT has enabled CDC to describe trends in cervical lesions (CIN2+) that could progress to cancer and the reduction of vaccine-preventable cancer-causing HPV types (such as HPV16 and HPV18) in women diagnosed with these cervical lesions. Monitoring high-grade cervical lesions serves as an early indicator of vaccine impact.
In this surveillance project, we monitor these cervical lesions among women age 18 and older in five different communities around the United States.
- We collect demographic and clinical information from laboratory and medical records for every woman who has a high-grade cervical lesion identified.
- For women aged 18-39 years, we also collect information such as insurance, cervical cancer screening history, and vaccination history.
- We obtain archived tissue specimens for HPV type testing for a panel of HPV types, including those targeted by HPV vaccines.
For more detailed information, see HPV-IMPACT study methods.
The main objectives of HPV-IMPACT are to:
- Monitor trends in overall incidence of high-grade cervical lesions (CIN2+) over time in defined populations;
- Monitor prevalence and distribution of HPV genotypes in women aged 18-39 years with CIN2+;
- Describe the demographic, clinical, and HPV type characteristics among patients with CIN2+;
- Estimate and monitor trends in cervical cancer screening utilization among residents of the catchment areas; and
- Estimate the proportion of patients with CIN2+ who received the HPV vaccine, and estimate vaccine effectiveness.
The HPV-IMPACT project is a collaboration between two groups at CDC: the Viral Vaccine Preventable Diseases Branch in the Division of Viral Diseases, which houses the epidemiology team, and the Chronic Viral Diseases Branch in the Division of High-Consequence Pathogens and Pathology, which houses the HPV laboratory.
Learn more about HPV-IMPACT surveillance areas and partners.